Most mutations that truncate the reading frame of the DMD gene cause loss of dystrophin expression and lead to Duchenne muscular dystrophy. However, amelioration of disease severity has been shown to result from alternative translation initiation beginning in DMD exon 6 that leads to expression of a highly functional N-truncated dystrophin. Here we demonstrate that this isoform results from usage of an internal ribosome entry site (IRES) within exon 5 that is glucocorticoid inducible. We confirmed IRES activity by both peptide sequencing and ribosome profiling in muscle from individuals with minimal symptoms despite the presence of truncating mutations. We generated a truncated reading frame upstream of the IRES by exon skipping, which led to synthesis of a functional N-truncated isoform in both human subject-derived cell lines and in a new DMD mouse model, where expression of the truncated isoform protected muscle from contraction-induced injury and corrected muscle force to the same level as that observed in control mice. These results support a potential therapeutic approach for patients with mutations within the 5′ exons of DMD.
Mutations in the DMD gene result in either the more severe Duchenne muscular dystrophy (DMD) or the milder Becker muscular dystrophy (BMD). The phenotype generally depends on whether the mutation results in the complete absence of the protein product dystrophin (in DMD) or preserves a reading frame that allows translation of a partially functional dystrophin protein (in BMD) 1 . We previously identified a particular BMD founder allele (c.9T>G; p.Trp3X) that did not follow this reading frame rule 2, 3 . Although this nonsense mutation is predicted to result in no protein translation, muscle biopsy revealed considerable amounts (~21%) of dystrophin expression of minimally decreased size, and the clinical phenotype is one of a very mild dystrophinopathy 2 . In cellulo and in vitro translation studies demonstrated that in subjects with p.Trp3X, translation is initiated from AUG codons in exon 6, suggesting alternative translation initiation as a mechanism of the phenotypic amelioration 4 , and we proposed that altered translation initiation may be a general mechanism of phenotypic rescue for 5′ mutations in this gene 4 , a prediction supported by a subsequent report 5 . Together, the clinical and experimental data in these studies demonstrated translation of a protein product that is derived from initiation within exon 6 and is highly functional despite missing half of the canonical actin-binding domain 1 (ABD1) region of the protein, which has been previously proposed to be essential for protein function 6 .
Protein translation initiation is commonly understood to occur by cap-dependent initiation 7 . IRESs are RNA regulatory sequences that govern cap-independent translation initiation in eukaryotic cells, which is activated when cap-dependent translation is compromised (for example, during cell stress) 8 . Ribosomes are recruited directly to these IRESs on the mRNA and can then continue scanning in a 5′ to 3′ direction for alternative initiation codons. They were first described in viruses, and among the earliest characterized was the encephalomyocarditis virus (EMCV) IRES 9 . Approximately 85 cellular IRESs have been described to date and are mainly located in 5′ untranslated regions (UTRs); for example, the 5′ UTR of utrophin A, an autosomal homolog of dystrophin, contains an IRES that is both particularly active in regenerating muscle and inducible by exposure to glucocorticoid treatment (the mainstay of therapy for DMD) 10, 11 . However, other eukaryotic IRESs have been described within coding sequences [12] [13] [14] [15] [16] , and some have also been implicated in the modulation of pathology, including an IRES in the APC gene that is linked to a mild version of familial adenomatous polyposis coli 17 .
In DMD, the mechanism by which efficient alternative translation initiation ameliorates disease in p.Trp3X and other 5′ mutation alleles has not yet been explained. Our results demonstrate the presence of a coding-region IRES in DMD as well as the functionality of the resultant dystrophin isoform, and they suggest a new route for therapy for approximately 6% of patients with DMD.
RESULTS

Evidence for IRES-induced translation in human muscle
We previously predicted that nonsense and frameshifting mutations leading to a stop codon within at least the first two DMD exons should result in the mild BMD phenotype via exon 6 translation initiation 4 . However, duplication of exon 2, which is the most common singleexon DMD duplication and which results in a premature stop codon within the duplicated exon 2 sequence, would seem to be an exception to this prediction, as it is usually associated with DMD 18 . A deletion of exon 2, which also results in a premature stop codon, has not been described, either in our large cohort 3 or in other large publicly available catalogs (http://www.dmd.nl/). We interpreted this lack of reported cases to mean that the clinical features in patients with exon 2 deletions are either asymptomatic or exceedingly mild as a result of expression of the N-truncated isoform.
We confirmed this interpretation after we detected a deletion of exon 2 (DEL2) in an Italian boy who first presented at age 6 years for evaluation of an incidentally detected elevation of serum creatine kinase (550 IU L −1 ; normal value <200 IU L −1 ). He reportedly met early motor milestones and no muscular dystrophy was ever reported in the family. His neurological examination was entirely normal at 15 years of age. Muscle biopsy showed slight fiber size variability (Supplementary Fig. 1a ) and, in some sections, an increased number of central nuclei, along with some densely stained hypercontracted fibers. Immunofluorescence analysis using a C-terminal antibody showed the presence of dystrophin at the sarcolemmal membrane ( Supplementary Fig. 1b ) that western blot analysis revealed to be of a smaller molecular weight (~410 kDa) than full-length dystrophin (Fig. 1a) , and mutational analysis revealed a deletion of exon 2 (Supplementary Fig. 1c-g) . Peptide sequencing using tandem mass spectrometry (LC-MS/MS) 19 confirmed the absence of any residues encoded by exons 1 through 5, consistent with translation initiation within exon 6 ( Fig. 1b and Supplementary Table 1) .
In a complementary approach, we examined DMD translation efficiency, promoter usage and alternative splicing using muscle RNA isolated from an individual with mild BMD with an exon 2 frameshift mutation (c.40_41del (p.Glu14ArgfsX17)) whose muscle western blot also revealed expression of the same smaller-molecular-weight dystrophin (~410 kDa) lacking the N-terminal epitope ( Fig. 1c and Supplementary Fig. 2a ). We used muscle homogenate to construct RNA sequencing (RNA-seq) libraries for ribosome-protected fragments (RPFs) and for total RNA. We compared the mRNA translation efficiency in an archived histopathologically normal muscle sample versus the frameshift-containing muscle using the ratio of reads from RPFs to reads from RNA-seq. Among the top 1,000 most abundant muscle mRNAs, DMD showed the greatest change in translation efficiency ( Fig. 1d) , indicating an approximately fivefold reduction in the amount of ribosomes translating the DMD muscle transcript in the subject with the frameshift mutation. This decreased amount of translation is consistent with both the expected reduction in dystrophin level given the subject's mild BMD phenotype and with the amount of dystrophin seen in individuals with p.Trp3X (ref. 4 ) and other 5′ mutation alleles (Fig. 1c) .
The saw-tooth RNA-seq pattern observed in DMD introns 1 through 8 ( Fig. 1e) confirmed that the major transcription start was located at the dystrophin muscle-specific promoter (Dp427m) and that DMD exons 1 through 7 underwent efficient co-transcriptional splicing 20 in both the control sample and the sample from the subject with the frameshift mutation. Two alternative 427-kDa isoforms of dystrophin (Dp427p and Dp427c) are expressed primarily in the central nervous system and differ from Dp427m only in the use of alternative exon 1 sequences. The lack of a strong nascent RNA signal from either the Dp427p or Dp427c promoters confirmed that upregulation of alternative promoters does not contribute to alternative AUG usage in exon 6 ( Fig. 1e) . In both samples, RNA-seq reads spanning exonexon junctions mapped exclusively to the known junctions between Dp427m exon 1 and exon 11, indicating that splicing of novel 5′ UTRs from alternative promoters did not contribute to exon 6 AUG usage. The distribution of ribosome footprints mapped on Dp427m exons 1 through 11 revealed normal levels of exon 1 AUG initiation, followed by premature termination in exon 2 and resumption of translation following the exon 6 in-frame AUG codons ( Fig. 1f ) that continued into the body of the DMD transcript ( Supplementary Fig. 2b-d) , consistent with efficient alternative translation initiation.
In vitro and cell-based assays
Having demonstrated new evidence for efficient alternative translation initiation using both ribosome profiling and protein analysis directly in muscle from individuals with attenuated phenotypes, we sought to characterize the elements contributing to the high translation efficiency. To determine whether exons 1 through 5 of DMD contain an IRES, we cloned the 5′ portion of the cDNA encompassing exons 1 through part of exon 6, beginning at the +4 position to exclude the native AUG initiation codon (c.4_c.369, referred as exon 1 to 6), into the dicistronic dual luciferase reporter vector pRDEF 21 . In each case, we included 49 nucleotides (nt) from exon 6 that placed the exon 6 AUGs in frame with the downstream FLuc reporter. This sequence corresponds to the first 39 nt, inclusive of the two in-frame AUGs (M124 and M128), and ten additional nucleotides used for cloning purposes. We generated T7 polymerase-generated RNAs from the different constructs and used them to perform rabbit reticulocyte lysate (RRL) translation assays ( Fig. 2a) . We checked the size and integrity of the corresponding RNAs using a formaldehyde agarose gel 22 (Fig. 2b) . Cap-independent translation activity (represented as the ratio of downstream FLuc to the RLuc luminescence) of exons 1 through 5 of DMD resulted in a 1.5-to 1.7-fold increase in FLuc signal, less than the 3.4-to 3.8-fold increase seen with the control EMCV IRES but still consistent with IRES activity ( Fig. 2a) .
RRL-based translation may underestimate IRES activity of either viral or eukaryotic cellular IRESs, possibly owing to the limiting amounts of RNA-binding proteins in this specialized extract or to the lack of tissue-specific IRES trans-acting factors (ITAFs) 23 . Therefore, we performed the assay in C2C12 mouse myoblasts, which express dystrophin, and we observed that the presence of the exon-1-to-6 construct led to approximately eightfold-higher FLuc expression relative to vector containing exon 6 alone ( Fig. 2a) . This represents ~50% of the activity of the control EMCV IRES, suggesting the presence of a relatively strong IRES within exons 1through 5. To map the position of the IRES, we cloned deletion constructs consisting of the 5′ portion of the DMD gene (exons 1 through 5) or appropriate controls into pRDEF. Deletion of the first 300 nt of this sequence did not significantly change the FLuc expression, whereas removal or inversion of the last 71 nt (representing nearly all of exon 5) completely abrogated expression of the FLuc reporter, and further deletions within exon 5 resulted in greatly reduced FLuc expression to levels not significantly different from exon 6 alone ( Fig. 2c) . We repeated the experiments in human embryonic kidney 293K cells, which do not endogenously express dystrophin, and in a commercial human myoblast cell line (hSKMM cells). Unlike the ECMV IRES, the DMD IRES did not stimulate FLuc expression in 293K cells, whereas the level of stimulation in hSKMM cells replicated the C2C12 results ( Supplementary Fig. 3a ), suggesting that the IRES is preferentially active in muscle.
We performed control experiments to exclude the possibility of aberrant splicing events, cryptic promoter activities or other potential artifacts leading to misinterpretation of the dicistronic assay 24, 25 . We removed the upstream SV40 promoter to generate a promoterless version of the pRDEF vector containing the exon 1 to 6 (c.4_c.369) DMD sequence. Transfection of this construct into C2C12 myoblasts showed only minimal background luminescence from both RLuc and FLuc, arguing against any cryptic promoter activity in the DMD coding sequence (data not shown). We did not detect any aberrant splicing by RT-PCR ( Fig. 2d, Supplementary Fig. 3c ), and we confirmed the RNA integrity by a northern blot analysis ( Fig. 2e and Supplementary Fig. 3b ).
Although either duplication or deletion of exon 2 results in an interrupted reading frame, the disparate associated clinical phenotypes led us to the hypothesis that IRES activity may be diminished in the presence of an exon 2 duplication. We tested this hypothesis in C2C12 cells and found that IRES activation was equivalent between the full-length (exons 1 through 6) and exon 2-deleted cDNAs but was markedly reduced in the presence of an exon 2 duplication ( Fig. 2f) , confirming that duplication but not deletion of exon 2 ablates IRES activity.
Activation by out-of-frame exon skipping and glucocorticoids
In considering skipping of exons before the exon 5 IRES, only the removal of exon 2 will disrupt the reading frame and result in a premature stop codon ( Fig. 3a) . This leads to the possibility that deletion of this exon could be used therapeutically to increase activation of the IRES, whether by use of antisense oligonucleotides (AONs) 26 or by use of adeno-associated virus-U7 (AAV-U7)-mediated antisense delivery 27, 28 . We selected four different sequences ( Fig. 3b ) for U7 small nuclear RNA (snRNA) targeting and cloned each into AAV1 to assess exon-skipping efficiency in myoblasts generated from either wild-type or exon 2 duplication fibroblast cell lines that express a doxycyclineinducible MyoD (referred to as FibroMyoD) 29 . All constructs were able to skip either one or two copies of exon 2 (Supplementary Fig. 4) .
In order to increase skipping efficiency, we cloned two copies each of constructs C and AL (Fig. 3b ) into a single self-complementary AAV1 vector (termed AAV1.U7-ACCA). We used a known antisense sequence (AON H2A) as a positive control of skipping 30 . Infection of FibroMyoD cells resulted in 88.6% of the DMD transcript having complete skipping of exon 2 and leading to the production of N-truncated dystrophin (Fig. 3c,d and Supplementary Fig. 5a ).
We tested the ability of the AAV1.U7-ACCA vector to skip exon 2 in vivo in a newly generated mouse model carrying a duplication of Dmd exon 2 on a C57BL/6 background (the Dup2 mouse; A.V., N.W., T. Simmons, A. Rutherford, A.F. et al., unpublished data). The resulting Dmd mRNA contains two copies of exon 2, disrupting the reading frame and resulting in nearly complete absence of dystrophin expression. We injected AAV1.U7-ACCA (5 × 10 11 vector genomes) directly into the tibialis anterior muscle in 6-to 8-week-old Dup2 mice (n = 5) or C57BL/6 (BL/6) control mice. Four weeks later, RT-PCR analysis from injected muscles demonstrated nearly complete exon skipping of exon 2 in Dup2 and BL/6 mice ( Fig. 4a,b ). In Dup2 animals ( Fig. 4a ), Dup2 transcript was 5.1%, wild-type transcript was 8.6% and the Del2 transcript was 86.3% of total mRNA. In wild-type BL/6 animals ( Fig. 4b) , the wild-type transcript was 14.2% and Del2 transcript was 85.8%. Consistent with the RT-PCR results, the saw-tooth RNA-seq pattern observed in Dmd introns 1 and 2 confirmed the suppression of co-transcriptional splicing of the duplicated exon 2 as well as the high efficiency of co-transcriptional splicing of exon 1 to exon 3 in the AAV1.U7-ACCA-injected mice ( Fig. 4c) . Western blot and immunostaining analyses showed expression of the N-truncated protein ( Fig. 4d) . Sarcolemmal staining was restored for β-dystroglycan and neuronal nitric oxide synthetase (nNOS) ( Fig. 4e ), suggesting the presence of a functional dystroglycan complex. The dystrophin protein induced in BL/6 male mice injected with AAV1.U7-ACCA was of the same size as that expressed in the Dup2 AAV1.U7-ACCA-injected animals, confirming the size difference between this protein and the full-length isoform ( Fig. 4d and Supplementary Fig. 5b ).
To demonstrate that this isoform restores membrane integrity, we subjected treated and untreated Dup2 mice to a downhill running protocol and injected them with Evans blue dye (EBD), which enters skeletal muscle fibers that have been permeabilized by membrane damage. Following intraperitoneal injection of EBD, we found uptake only in fibers without dystrophin staining ( Fig. 4f) , suggesting the N-truncated protein stabilizes the sarcolemma and providing further evidence for the functionality of this protein in vivo.
To examine the effect of glucocorticoid exposure on the DMD IRES, we assayed exon 5 IRES activity using the exon-5-to-6 construct ( Fig. 2c ) in C2C12 cells in the presence of increasing concentrations of 6-methyl-prednisolone (PDN) and found that downstream FLuc activity increased in a dose-dependent fashion from around sevenfold change in the absence of PDN to over 20-fold at 6.4 µM PDN (Fig. 5a) . We did not observe this glucocorticoid-mediated activation after transfection of control constructs containing exon 6 alone or an inverted exon 5 or in 293K cells ( Fig. 5a and Supplementary Fig. 6a ). We saw an increase in dystrophin expression in Dup2 FibroMyoD cells treated with 6.4 µM PDN (Fig. 5b) , and treatment of Dup2 mice (n = 5) with both U7-ACCA and PDN resulted in an increase in truncated dystrophin expression compared to that in mice injected with U7-ACCA alone (Fig. 5c,d) , consistent with the idea that the DMD IRES is inducible by glucocorticoids. We observed an increase to less than 3% of BL/6 levels with injection of PDN alone in some Dup2 mouse muscle samples ( Fig. 5c ), suggesting some leakiness of the IRES in the Dup2 mouse model.
In all cases, this increase in truncated dystrophin expression was not due to a difference in the AAV vector genome copy number ( Supplementary Fig. 6b ). Supplementary Fig. 5a ). 7   649   15  CH1  119  131  CH2  237   17 ABS1 26  88 ABS2 116  131 ABS3 148   ABD1   1  32  62 63  88 89  119  31  11  176  120  216  277  176 216   93  186  264  357  530 Because utrophin translation may be regulated by corticosteroids and overexpression of utrophin can compensate for the absence of dystrophin, we assessed utrophin levels in the same injected muscles (Fig. 5e) . In Dup2 animals not injected with AAV1.U7-ACCA or with PDN, utrophin levels were increased in comparison to those in BL/6 mice, similar to what has been reported in mdx, the standard dystrophinopathy mouse model 31 . Comparison of the four groups (untreated Dup2, Dup2 injected with PDN, Dup2 injected with AAV1.U7-ACCA and Dup2 injected with both PDN and AAV1.U7-ACCA) revealed no statistically significant difference in utrophin levels between PDN-treated (1 mg/kg/d) and untreated animals (by Kruskal-Wallis) ( Fig. 5f) , confirming that treatment with PDN does not increase expression of utrophin.
N-truncated dystrophin stabilizes muscle in vivo
We examined whether expression of the IRES-driven isoform of dystrophin improved muscle integrity and physiology in Dup2 mice. Similar to the case in mdx mice, dystrophic changes in Dup2 mice are quantifiable at 4 weeks of age as widespread muscle regeneration characterized by centralized nuclei (A.V., N.W., T. Simmons, A. Rutherford, A.F. et al., unpublished data). One month after intramuscular injection of AAV1.U7-ACCA into the tibialis anterior muscle of 4-week-old Dup2 mice, expression of the IRES-driven isoform resulted in a significant reduction of centralized nuclei from 73.0 ± 1.6% of myofibers in untreated mice to 65.2 ± 2.2% in those treated with AAV1.U7-ACCA alone (Fig. 6a) . Quantification of the number of EBD-positive fibers confirmed that expression of the IRES-driven isoform resulted in significant protection of muscle fibers in these mice, from 14.7 ± 6.6% of myofibers in untreated Dup2 muscle to 2.8 ± 1.8% (AAV1.U7-ACCA alone) or 0.65 ± 0.5% (AAV1.U7-ACCA in combination with PDN) (Fig. 6b) .
Normalized maximum hindlimb grip strength (Fig. 6c ) in untreated Dup2 mice (2.22 ± 0.26 kg force (kgf) kg −1 mass of animal) was significantly lower than that observed in BL/6 mice (3.36 ± 0.37 kgf kg −1 ). Treatment with either AAV1.U7-ACCA alone (3.35 ± 0.32 kgf kg −1 ) or AAV1.U7-ACCA in combination with PDN (3.17 ± 0.28 kgf kg −1 ) resulted in significantly improved strength, to levels not significantly different from those observed with BL/6 mice (Fig. 6c) . Normalized specific force following tetanic contraction ( Fig. 6d) in untreated Dup2 animals (170.9 ± 14.3 mN mm −2 ) was significantly less than in BL/6 mice (274.0 ± 12.1 mN mm −2 ). Treatment with AAV1.U7-ACCA alone (236.04 ± 19.4 mN mm −2 ) or AAV1.U7-ACCA in combination with PDN (251.2 ± 10.4 mN mm −2 ) significantly increased force to a level not significantly different from that seen in BL/6 ( Fig. 6d) . Muscles injected with AAV1.U7-ACCA with or without PDN were significantly more resistant to contractioninduced injury than untreated Dup2 muscle, and the combination of both treatments showed no significant difference from BL/6 controls ( Fig. 6e) . Despite the minimal (<3%) expression of dystrophin induced by PDN in some Dup2 muscles (Fig. 5c) , treatment of the Dup2 muscles with PDN alone did not result in a significant amelioration in any of these measures of muscle physiology (Fig. 6) .
DISCUSSION
We have demonstrated the presence of a glucocorticoid-responsive IRES within DMD exon 5 that can drive the expression of an N-truncated but functional dystrophin. We confirmed the relevance of this IRES-induced isoform to the amelioration of disease severity by both ribosomal profiling of muscle from an individual with BMD due to a frameshift in exon 2, and by the mass spectrometric data from the first-ever reported case of an exon 2 deletion, found in an entirely asymptomatic subject. Finally, in a new therapeutic approach, we have induced out-of-frame exon skipping to generate a premature stop codon and consequently force activation of the IRES in both human cell lines carrying a duplication of exon 2 and in a new DMD mouse model, in which we restored components of the dystrophin complex and corrected the pathologic and physiologic features of muscle injury.
Most eukaryotic mRNAs are monocistronic and possess a specialized cap structure at their 5′ terminus that is required for translation initiation, as this is where scanning by the 40S ribosomal subunit begins 32 . Despite clear evidence for the cap-dependent 5′ to 3′ scanning model of initiation, bioinformatic analysis has suggested that ~50% of human transcripts contain 5′-UTR short upstream open reading frames (uORFs) that may mediate transcript-specific translation efficiency and control 33 . uORFs may function by modulating either leaky scanning 34 or termination-dependent reinitiation 35, 36 , although uORFs can also dynamically regulate access to IRES elements, as shown for the mammalian cationic amino acid transporter 1 gene SLC7A1 (ref. 37) . Given the cautions previously raised regarding IRES identification via reporter assays 24 , all control experiments performed in this study, including assessment of RNA integrity by RT-PCR and northern blot analyses, use of a promoterless plasmid and use of an appropriate positive IRES control, were consistent with cap-independent initiation due to IRES activity. We mapped a minimal region harboring a DMD IRES activity to 71 nt, a small length compared to EMCV (588 nt) but similar in size to that identified in the c-myc 5′ UTR (50 nt) 38 . This is an important feature, as such small IRESs can be used in dicistronic vectors, where space is limited when packaged into viral vectors such as AAV.
Although the precise molecular mechanism by which cellular IRESs modulate translation has not been defined in the literature, the requirement for ITAFs has been strongly suggested 39 . These cellular proteins act in trans to augment IRES activity. Almost all ITAFs have been shown to harbor RNA-binding domains and have been hypothesized to act as RNA chaperones, helping the IRES primary sequence attain the appropriate conformational state intrinsic to its activity 40 . This is probably relevant to the loss of DMD IRES activity in the presence of an exon 2 duplication, which may ablate IRES function by formation of a complex secondary structure or cause the formation of an inhibitory uORF that interferes with ITAF access to the exon 5 IRES.
Our results provide a molecular explanation for the rescue of 5′ truncating mutations via a heretofore undescribed mechanism of post-transcriptional regulation of dystrophin expression. The identification of this new cellular IRES and the resultant dystrophin isoform has major implications for understanding the basic biology of muscle and dystrophin. We note that exon 5 of DMD is highly conserved, with the dog, mouse, horse and chicken DMD genes showing 87% identity to the human DMD and 39 species, including Danio rerio and Xenopus tropicalis, having genes with 67% identity. The presence of an IRES within such a highly conserved region strongly suggests selective pressure favoring a programmed role for alternative translation initiation. The role of the DMD IRES under normal conditions is unclear, but ongoing efforts to understand the relevant cell lineage-specific and/or conditional activation signals will shed light on the underlying mechanisms of DMD IRES control and elucidate potentially new functions of dystrophin.
An unanswered question is how the N-truncated isoform remains functional. A key cellular role for dystrophin is presumed to be transmitting the force of contraction across the sarcolemma to extracellular structures by serving as an important architectural bridge between the F-actin cytoskeleton and the muscle plasma membrane 41, 42 . Two regions within dystrophin are responsible for F-actin binding: ABD1 (spanning residues 15-237) and ABD2 (spanning residues 1468-2208). A number of studies have shown a lack of stability of dystrophin in the setting of deletions within the ABD1 domain 6, [43] [44] [45] [46] . However, we note that most of these studies were performed with microdystrophin constructs lacking the ABD2 domain, which has been shown to enhance the interaction between ABD1 and actin 47 . Such miniproteins bind actin and modify actin dynamics in a different manner compared to the full-length version 48, 49 . Although results with such constructs show that absence of ABD2 does not completely abrogate binding of dystrophin to actin, it is unlikely that absence of ABD1 completely disrupts the interaction between dystrophin and actin. Expression of transgenes deleted for ABD1 lessens the mdx phenotype and restores the costameric pattern of the M band and Z lines, suggesting that the link between dystrophin and the subsarcolemmal cytoskeleton involves more than an interaction with ABD1 (ref. 50, 51) . In agreement with this, other members of the cytoskeleton have been shown to interact with the dystrophin spectrin repeat [52] [53] [54] .
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as well as reports of other individuals with BMD lacking part or all of the ABD1 domain [56] [57] [58] , clearly indicate the considerable functionality of the IRES-driven N-truncated isoform despite its lack of the first half of the canonical ABD1. This is particularly noteworthy because forcing expression of this isoform by generating an out-of-frame transcript in order to induce IRES activity holds substantial therapeutic potential. This out-of-frame strategy could be combined with glucocorticoid treatment, a drug already used in patients with DMD and BMD, which should increase IRES activation. Of note, rather than being a personalized exon-skipping approach for patients with exon 2 duplications (who represent nearly 2% of individuals with DMD in one large series 3 ), out-of-frame skipping of exon 2 to induce expression of the truncated protein might help all individuals who harbor mutations at the 5′ end of the DMD gene (up to 6% in the same cohort 3 ). Additionally, the out-of-frame strategy might be more broadly applicable to other genes with a coding-region IRES, such as the tumor suppressor gene APC 17 .
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The RPF-seq and RNA-seq data discussed have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO Series accession number GSE56148. 
ONLINE METHODS
Reporter constructs. Dicistronic dual luciferase vector pRDEF (a gift from P. Sarnow) was used to study cellular IRES activity 59 (Fig. 2e) . Transcription of a dicistronic transcript is driven either by the T7 promoter (for in vitro assays) or by the SV40 promoter (for in cellulo or in vivo) assays. The upstream Renilla luciferase (RLuc) open reading frame (ORF), under the control of the SV40 promoter, is terminated by two in-frame stop codons. This is followed by a mutated nonfunctional defective EMCV (dEMCV) sequence that forms a secondary structure previously demonstrated to prevent readthrough by the translation-competent ribosomal complex (and hence continued scanning) 59 (Fig. 2e) . Downstream of the dEMCV structure is a multiple cloning site, where all sequences of interest where cloned, followed by an ORF for firefly luciferase (FLuc). Desired fragments were amplified by PCR using 5′ and 3′ primers that both contained an EcoRI site. Amplified DNA was cleaved with EcoRI and inserted into the pRDEF vector between the deficient EMCV IRES and the firefly coding sequence at the EcoRI restriction site.
All primers used to synthesis reporter constructs are available upon request. eMCV (Encephalomyocarditis virus) IRES sequence was amplified from pWPI (Addgene). Exon 2 duplication was amplified from cDNA obtained from RNA of human subject-derived cell lines harboring a duplicated exon 2. Promoterless version of the different constructs were generated by digesting the vector with BglII and HindIII. All plasmids constructs were sequence verified. The mouse U7 snRNA gene and smOPT sequence were designed, modified and cloned following the protocol described in ref. 60 . Exonic splicing enhancer (ESE) and exonic splicing silencer (ESS) sequences were identified by Human Splicing Finder. Multiple U7 snRNA constructs were cloned in tandem in a self-complementary AAV vector using an XbaI restriction site. All plasmids constructs were sequence verified. Both ITR and self-complementary AAV backbone were checked using SmaI and MscI, respectively. Technologies) were incubated and plated in opaque 96-well half-area plates (Costar). Cells were trypsinized, washed and added at a concentration of 50,000 cells/well in 50 µl Opti-Mem. Transfected cells were incubated overnight at 37 °C in 5% CO 2 , then 75 µl DMEM+10% FBS were added to each well, and the plates were incubated for an additional 24 h.
Patient fibroblast cultures were derived from a skin biopsy. Primary human cells were extracted from biopsies by enzymatic dissociation with collagenase 1A (Sigma-Aldrich). Cells were expanded in the proliferation medium composed of DMEM, 20% FBS (FBS), 100 mg/mL penicillin, 100 mg/mL streptomycin and l-glutamine (Life Technologies).
For htert-puromycin and doxycycline inducible Myo-D-hygromycin fibroblast infection, 2 × 10 3 to 6 × 10 3 cells/cm 2 were plated into a 12-well plate. At 50% confluence, 2 to 5 × 10 9 vg/mL of each lentivirus were added into 400 µL of the proliferation medium. The following day, 1 ml of proliferative medium was added. One to two days later, cells were split into 6-well plates and grown until 70% confluency. Then proliferative medium was complemented with 400 µg/ml of hygromycin and 1 µg/ml of puromycin, and cells were maintained under selection for 12 days.
Primary human myoblasts from the subject with the exon 2 duplication and wild-type positive control were obtained from muscle biopsies (for the wild-type control, muscle was obtained from a 9-year-old healthy male in the course of orthopedic surgery for a fracture) (Supplementary Fig. 4b) . Myotubes obtained after incubation by culturing in differentiation medium (2% FBS) were transfected with AON-H2A (100 nM) in the presence of polyethylenimine (PEI, ExGen500, MBI Fermentas) (2 µl per µg of AON) as transfection reagent, as previously described 61 .
Dual luciferase assay. Luciferase activities were determined using the Dual Luciferase Reporter (DLR) Assay System (Promega). Relative light units were measured on a Veritas microplate luminometer (Turner BioSystems). Transfected cells were lysed in 20 µl of lysis buffer (PLB, provided with the kit), and light emission was measured following injection of 25 µl of each luminescence reagent. Expression of the second cistron was calculated by comparing firefly/Renilla luciferase ratios of experimental constructs with those of control constructs: (firefly experimental RLUs/Renilla experimental RLUs)/(firefly control RLUs/Renilla control RLUs). The experiment was repeated 3 times (for RRL and C2C12), and Figure 2a shows a representative result. For each experiment, luciferase activity for a given construct was measured in 8 luminometer wells, then averaged and the s.d. (bars) calculated. Data points that fell greater than one s.d. from the mean were discarded as outliers, and the mean and s.d. recalculated. Figure 2e ,f is a representative example of results obtained after transfection of the different constructs, which were transfected 3 times. The same applies for Supplementary Figures 3 and 6 .
For each construct, numbering is based upon the Dp427m cDNA sequence; the full-length construct pRdEF+4+369 (exons 1 to 6) begins at the +4 position to exclude the native AUG initiation codon. Exon 6 was preserved, and AUG2 (M124) and AUG3 (M128) were cloned in frame with the downstream FLuc reporter. FLuc luminescence (cap-independent) is expressed as a percentage of RLuc luminescence (cap-dependent) after transfection of the dicistronic constructs in C2C12 cells. All results were normalized to the exon 6 alone vector, the FLuc:RLuc ratio of which was set at a value of 1. Statistical analysis was performed using a Kruskal-Wallis test, comparing the results for each construct versus the exon 6 alone vector, which resulted in levels of expression comparable to an entirely empty vector (P > 0.99).
In vitro transcription and in vitro translation. T7 PCR products were generated using a forward T7 primer and a reverse primer located at the end of the SV40 polyA signal. The corresponding PCR product was gel purified using a gel extraction kit from Qiagen. In vitro transcription was performed using the T7 MEGAscript kit (Life Technologies). The RNA produced was then purified using a MEGAclear kit according to the manufacturer's protocol (Life Technologies). Rabbit reticulocyte lysate (RRL)-based in vitro translation reactions were done using the Rabbit Reticulocyte Lysate System Nuclease Treated kit (Promega) according to the manufacturer's instructions. Reactions were set up in a final volume of 25 µl using 100 ng of purified RNA, 1µl of RNAsin (Promega) and 17.5 µl of RRL. The reaction was incubated 1 h at 37 °C and stopped by adding 100 µl of PLB (Promega).
Northern Blotting. RNA integrity and northern blotting was performed as previously described 22 . Total RNA was isolated from Hek293 or C2C12 cells using TRIzol (Ambion). Twenty microgram RNA was resolved on a 2% glyoxal agarose gel and transferred to nylon membrane using Turboblotter (Whatman) as per manufacturer's protocol. Radiolabeled DNA probe was synthesized by asymmetric PCR using firefly luciferase as template DNA. Probe and primers used are available upon request. The northern blot from in vitro experiment was performed from two independent experiments. Ribosome profiling. Tissue homogenates were prepared from 40 frozen tenmicron sections of muscle biopsy obtained from a patient with a c.40_41delGA mutation and a normal control. Sections were lysed by 20 passages through a 26-gauge needle after addition of 500 µl of ice-cold 20 mM Tris HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl 2 , 1 mM DTT, 1% Triton X-100 and 100 µg/ml cycloheximide (Sigma). For RNA-seq, 100 µl of lysate was added to 300 µl of TRIzol LS reagent (Life Technologies), and total RNA was extracted according to the manufacturer's specifications. For RPF-seq, 6 µl of RNase I (100 U/µl, Ambion) and 3 µl of Turbo DNase (2 U/µl, Ambion) was added to 250 µl of lysate and incubated at room temperature with gentle agitation. After 90 min, 750 µl of TRIzol LS reagent was added and RNase-resistant RNA fragments were isolated by extraction. RNA fragments were electrophoresed on a denaturing 15% polyacrylamide TBEurea gel (Life Technologies, EC68852BOX). The gel region containing 26-38 nucleotide size RNA fragments was excised and RNA isolated by passive elution. Gel-purified RNA fragments were treated with 5 units of Antarctic Phosphatase (5 U/µl NEB) in the presence of 40 units of RNase Inhibitor (40 U/µl, Ambion) for 30 min at 37 °C, followed by 5 min at 65 °C to deactivate the enzyme. Fragments were then treated with 20 units of T4 polynucleotide kinase (10 U/µl NEB) for 60 min at 37 °C and purified using RNeasy MinElute columns (Qiagen) according to the manufacturer's recommendations for small RNA. RPF-seq libraries were built using the TruSeq Small RNA Sample Preparation Kit (Illumina) according to the manufacturer's specifications, using Superscript II (Invitrogen). After PCR to enrich for ligated fragments, the final gel purification was eliminated and instead the amplified library samples were cleaned using 50 µl of AMPure XP magnetic beads (Agencourt) according to the manufacturer's specifications. For RNA-seq libraries, 4 µg of TRIzol-extracted total RNA from each sample was depleted for rRNA using Ribo-Zero rRNA Removal Kit Human/Mouse/Rat (Epicentre). The rRNA-depleted total RNA was then processed using the TruSeq RNA Sample Preparation v2 Kit (Illumina) according to the manufacturer's specifications using Superscript II (Invitrogen). RPF-seq and RNA-seq libraries were subjected to 50 cycles of single-end sequencing on an Illumina HiSeq 2000 instrument. Trimmed and filtered RPFand RNA-seq reads were mapped to RefSeq FASTA sequences downloaded from the UCSC genome browser (hg19 assembly) using cross_match. Custom Perl scripts were used to generate read count tables from mapped RPF and RNA-Seq reads, and edgeR (Bioconductor) was used for model-based read count normalization. Library-size normalization from the read count data was done using the calcNormFactors function from the edgeR package and was used to scale the count data by raw library size, and normalized read count data from RefSeq CDS regions was used to calculate the translation efficiency.
Ribosome profiling data was used to compute a translation efficiency (TE) metric for each of the 1,000 most abundant transcripts (by mRNA mass) from patient FS (c.40_41del) and normal control muscle. TE value for each gene was calculated from the normalized number of ribosome footprint sequence reads divided by the number of RNA-seq reads mapped within the coding (CDS) sequence. The rank transcript abundance of the top 1,000 genes was computed from the total number of mapped reads per transcript.
Myoblast/myotube induction. For myoblast/myotube induction, poly-dlysine and laminin-coated 10-cm dishes were used (354455, BD Biosciences). For myoblast/myotube induction, fibroblasts were plated in the 10-cm laminincoated dish at 50% confluency max. Media was changed to myoblast media when cells reached 70% confluency (SkBM-2 complete, Promocell) + 4 µg/ml of freshly made doxycycline. When myoblasts reached 95% confluence, media was switched to myotube media (C-23061, Skeletal Muscle Cell Differentiation Medium, Promocell) + 4 µg/ml of fresh doxycycline 61 . Medium was changed every 4 days. Cells were collected at day 14 post-differentiation for protein extraction.
AAV production. rAAV vectors were produced by a modified cross-packaging approach whereby the AAV type 2 inverted terminal repeats can be packaged into multiple AAV capsid serotypes. Using a standard 3-plasmid DNA calcium phosphate CaPO 4 precipitation method, AAV productions were performed in HEK293 cells. Cells were maintained in DMEM supplemented with 10% cosmic calf serum (Thermo Scientific) and penicillin and streptomycin. The production plasmids were: (i) pAAV.U7.antisense, (ii) rep2-cap1-modified AAV helper plasmids and (iii) an adenovirus type 5 helper plasmid (pAdhelper) expressing adenovirus E2A, E4 ORF6 and VA I/II RNA genes. Viral particle were purified from clarified 293 cell lysates using sequential iodixanol gradient purification and anion-exchange column chromatography by a linear NaCl salt gradient, and titration of the encapsidated viral genome were performed using a quantitative PCR-based titration method runned on a Prism 7500 Taqman detector system (PE Applied Biosystems) 62 . The primer and fluorescent probe targeting the U7 promoter and corresponding sequences are available upon request.
AAV infection in vitro. Self-complementary AAV1 infection was performed when myotube media was added. 1 × 10 11 vg was used in 600 µl of differentiation media for a 6-well plate and 5 × 10 11 vg in 3.5 ml for a 10-cm plate. The following day, differentiation media was added to the infected cells. Infection was performed twice, and each time RNA was extracted for RT-PCR analysis of exon 2 inclusion or exclusion, with identical results; a representative image is shown in Figure 3 and Supplementary Figure 4 .
Injection. Two-month-old mice were injected in the tibialis anterior (TA) with 5 × 10 11 vg/ml of AAV1-U7-ACCA in 50 µl total of phosphate-buffered saline (PBS) or with PBS only, using a 33-G gas-tight Hamilton syringe. Four weeks after, mice were killed and both TA muscles were removed.
Glucocorticoid treatment. 1 mg/kg/day of alpha-methylprednisolone (PDN, M3781, Sigma) was administered by intraperitoneal injection (IP) for 3 weeks. Control animals received PBS.
RNA extraction. RNA extractions were performed on the pellet after protein extraction. Pellets were rinsed and 1 ml of TRIzol (Life Technologies) was added. Cell lysate was then homogenized by pipetting and incubated for 5 min at RT. Cell lysate was transferred into a 1.5-ml tube and 0.2 ml of chloroform was added for 1 ml of TRIzol and shaken manually for 15 s. Mixed solution was then incubated for 2-3 min at RT and finally centrifuged for 15 min at 12,000g (+4 °C). Aqueous phases (the upper one) were then collected and transferred into a new tube. 0.5 ml of isopropanol (per ml of TRIzol) was added and the mixture was allowed to stand for 10 min at RT. Supernatant was then removed after centrifugation at 12,000g for 10 min at 4 °C, and the pellet was washed with 1 ml of 75% EtOH (per ml of TRIzol). After centrifugation (7,500g 5 min at 4 °C), the pellet was air dried and the RNA was resuspended into RNase free water for 10 min at 60 °C.
Reverse transcription and PCR amplification.
This protocol is based on the manufacturer-optimized protocol (Maxima reverse transcriptase, Thermoscientific). 1 µg of RNA was converted into cDNA. Exon-exon junctional primers were used to amplify the region of interest. Primers, nucleotide sequences and PCR program are available upon request. PCR amplification was performed using Faststart PCR system (Roche).
Protein extraction and western blotting. Cell lysates (experiment performed in duplicate) and mouse TA muscle lysates were prepared using the same lysis buffer (150 mM Tris-NaCl, 1% NP-40, digitonin (Sigma) and protease and phosphatases inhibitors (1860932, Thermo)). The lysate was centrifuged at 14,000g for 20 min. Protein quantification was performed using BCA protein assay kit (Pierce). The supernatant was mixed with a classic SDS-PAGE buffer and boiled 5 min at 100 °C. 150 µg of protein samples were run on a precast 3-8% Tris-Acetate gel (NuPage, Life Science) for 16 h at 80 V (4 °C). Gels were transferred on a nitrocellulose membrane overnight at 300 mA. Rabbit polyclonal antibodies against the C-terminal end of dystrophin were used (1:250, PA1-21011, ThermoScientific or 1:400, 15277, Abcam). The hybridoma cell lines for the MANEX1A (clone 4C7, IgG1), MANCHO3 (clone 8A4) and MANDAG2 (clone 7D11, IgG1) monoclonal antibodies were from the MDA Monoclonal Antibody Resource (http://www.glennmorris.org.uk/mabs/WCIND.htm) 64 . Manex1A was used (1:50) only on human muscle samples to detect the full-length dystrophin, targeting an epitope in exon 1. Mancho3 was used (1:50) to stain utrophin. As loading controls, alpha-actinin (1:5,000, A-7811, Sigma) was used for mouse tissues, and myosin heavy chain (MF20 (1:200) , from the University of Iowa Developmental Studies Hybridoma Bank (DSHB)), was used for human cells. After 1 h incubation at RT, membrane was washed (5 × 5 min with 0.1% Tween in TBS, TBST) and exposed to the secondary antibodies (60 min at RT) at 1:1,000 dilution. All antibodies were diluted in 1/2 Odyssey blocking buffer (Licor) and 1/2 TBST. An anti-mouse IgG (H + L) (IRDye 680CW Conjugate) and an anti-rabbit IgG (H + L) (IRDye 800CW Conjugate) (Licor) were used at 1:1,000 dilution. 5 × 5 min with 0.1% Tween in TBS washes were performed followed by a ddH 2 O soaking. The two simultaneous IRDye signals were scanned using the LI-COR Odyssey NIR. For muscle sections, immunoblot was performed on each muscle in duplicate, and the signals for both dystrophin and α-actinin were quantified using ImageJ. The signals for both utrophin and α-actinin from the resulting 5 lanes were quantified using ImageJ.
Mass spectrometry. For liquid chromatography/tandem mass spectrometry (LC-MS/MS), in-gel reduction, alkylation and digestion were performed according
